Reduction‐responsive poly (ethylene glycol)‐dexamethasone biarm conjugate and its self‐assembled nanomicelles: Preparation,physicochemical characterization,and thiol‐triggered drug release

In this study, a reduction‐responsive poly (ethylene glycol)‐dexamethasone biarm conjugate was synthesized as intracellular targeted drug delivery carriers. The hydroxyl end group of methoxy poly (ethylene glycol) (mPEG) was modified to introduce a biarm structure with bioreducible disulfide bond and amine end groups. Dexamethasone (Dex) as a nuclear targeting moiety was conjugated to the amine end groups of mPEG biarm derivatives, mPEG‐(NH₂)₂ or mPEG‐(ss‐NH₂)₂, with or without bioreducible disulfide bonds. The bioreducible and nonreducible mPEG‐Dex biarm conjugates, R‐mPEG‐Dex and N‐mPEG‐Dex, were synthesized and characterized by various analytical methods, proton nuclear magnetic resonance (¹H‐NMR), Fourier transform infraredspectroscopy (FT‐IR), dynamic light scattering (DLS), and fluorescence measurements. Amphiphilic mPEG‐Dex conjugates self‐assembled in aqueous solutions to form nanoparticles (NPs) with a size range of 130 to 150 nm, and their critical micelle concentrations (CMCs) were determined to be 12.4 and 15.3 mg/L, respectively, for bioreducible and nonreducible ones. The R‐mPEG‐Dex NPs maintained good colloidal stability in the presence of bovine serum albumin (BSA) for more than 1 week but demonstrated a significant change in colloidal stability in the presence of dithiothreitol (DTT). In DTT‐containing phosphate‐buffered saline (PBS), the bioreducible NPs showed not only reduction‐responsive destabilization with PEG shedding but also thiol‐dependent drug release profile. Our observations indicated that the R‐mPEG‐Dex NPs have a promising prospective as an efficient nanocarrier for intracellular targeted delivery of various anticancer drugs.